该股主要指标及行业内排名如下： 证券之星消息，截至2025年12月16日收盘，可孚医疗(301087)报收于45.24元，上涨0.4%，换手率 0.86%，成交量1.67万手，成交额7519.34万元。 12月16日的资金流向数据方面，主力资金净流入1017.31万元，占总成交额13.53%，游资资金净流入 190.05万元，占总成交额2.53%，散户资金净流出1207.36万元，占总成交额16.06%。 近5日资金流向一览见下表： 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为 54.56。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法 ...

可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有7家机构给出评级，买入评级6家，增持评级1家；过去90天内机构目标均价为 54.56。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 ...

文/华夏大健康研究院 11月21日下午，由华夏时报社主办的"2025第五届华夏大健康产业发展暨康复服务大会"在北京成功举 行。本次大会以"智领健康未来"为主题，汇聚产业界、学术界、研究机构及投资方等多方代表，旨在整 合全链条资源，把脉行业趋势，探索发展路径。 现场设置了多场高水平圆桌对话，聚焦创新药、脑机接口、AI医疗、中医药转化等前沿议题，深入探 讨行业热点与突破方向。会议还集中发布并展示了一批具有示范意义与前瞻价值的创新典型案例，涵盖 赋能美好生活、ESG、创新药、中医药、生物科技、AI医疗、硬核科技与社会心理服务等八大类别，从 企业实践、技术应用、品牌建设与人物故事等多维度，展现了大健康领域的活力、深度与创新成果。 USANA葆婴：以科学之力，筑健康大家庭 USANA葆婴始终以"成为世界上最健康的大家庭"为愿景，从科学研发到产品质量，从体重管理到母婴 关怀再到全民健康，每一步都彰显着品牌对"美好生活"的深刻理解与务实行动。USANA葆婴将健康理 念融入产品设计，所有保健食品均获得国家注册或备案凭证，原料优质安心，生产过程严格遵循保健食 品GMP规范。这种对质量的执着追求，让USANA葆婴连续多年获得"消 ...

证券之星消息，截至2025年12月11日收盘，可孚医疗(301087)报收于45.47元，下跌1.2%，换手率 2.2%，成交量4.27万手，成交额1.96亿元。 12月11日的资金流向数据方面，主力资金净流出1740.11万元，占总成交额8.87%，游资资金净流入 851.25万元，占总成交额4.34%，散户资金净流入888.86万元，占总成交额4.53%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-11 | 45.47 | -1.20% | -1740.11万 | -8.87% | 851.25万 | 4.34% | 888.86万 | - 4.53% | | 2025-12-10 | 46.02 | 4.14% | -5083.32万 | -13.91% | 1989.34万 | 5.44% | 3093.98万 | 8.47% | | 2025-12-09 | | ...

证券之星消息，截至2025年11月28日收盘，可孚医疗(301087)报收于42.5元，上涨1.58%，换手率 0.48%，成交量9279.0手，成交额3926.1万元。 11月28日的资金流向数据方面，主力资金净流入200.86万元，占总成交额5.12%，游资资金净流出 184.07万元，占总成交额4.69%，散户资金净流出16.78万元，占总成交额0.43%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-28 | 42.50 | 1.58% | 200.86万 | 5.12% | -184.07万 | -4.69% | -16.78万 | -0.43% | | 2025-11-27 | 41.84 | 0.00% | -235.77万 | -7.21% | -140.26万 | -4.29% | 376.03万 | 11.50% | | 2025-11-26 | 41.8 ...

证券之星消息，截至2025年11月25日收盘，可孚医疗(301087)报收于41.63元，上涨0.65%，换手率 0.66%，成交量1.28万手，成交额5337.22万元。 11月25日的资金流向数据方面，主力资金净流入40.49万元，占总成交额0.76%，游资资金净流出128.34 万元，占总成交额2.4%，散户资金净流入87.85万元，占总成交额1.65%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-25 | 41.63 | 0.65% | 40.49万 | 0.76% | -128.34万 | -2.40% | 87.85万 | 1.65% | | 2025-11-24 | 41.36 | 1.17% | -567.49万 | -9.80% | 213.35万 | 3.68% | 354.14万 | 6.11% | | 2025-11-21 | 40.88 | -3. ...

证券之星消息，截至2025年11月24日收盘，可孚医疗(301087)报收于41.36元，上涨1.17%，换手率 0.72%，成交量1.4万手，成交额5792.63万元。 11月24日的资金流向数据方面，主力资金净流出567.49万元，占总成交额9.8%，游资资金净流入213.35 万元，占总成交额3.68%，散户资金净流入354.14万元，占总成交额6.11%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-24 | 41.36 | 1.17% | -567.49万 | -9.80% | 213.35万 | 3.68% | 354.14万 | 6.11% | | 2025-11-21 | 40.88 | -3.36% | -231.72万 | -3.35% | 315.85万 | 4.56% | -84.13万 | -1.22% | | 2025-11-20 | 42.30 ...

Core Viewpoint - The stock of Kefu Medical (301087) has experienced a decline, with a closing price of 40.88 yuan on November 21, 2025, down by 3.36% from the previous day [1] Financial Performance - Kefu Medical reported a total revenue of 2.398 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 6.63% [3] - The net profit attributable to shareholders for the same period was 260 million yuan, up by 3.3% year-on-year [3] - In Q3 2025, the company achieved a single-quarter revenue of 902 million yuan, a significant increase of 30.72% year-on-year [3] - The net profit for Q3 2025 was approximately 92.83 million yuan, reflecting a year-on-year growth of 38.68% [3] - The company’s gross profit margin stands at 53.35%, which is higher than the industry average of 51.22% [3] Market Position - Kefu Medical's total market capitalization is 8.54 billion yuan, which is below the industry average of 10.906 billion yuan, ranking 43 out of 124 in the medical device sector [3] - The company has a price-to-earnings (P/E) ratio of 24.61, significantly lower than the industry average of 54.54, ranking 24 out of 124 [3] - The price-to-book (P/B) ratio is 1.81, compared to the industry average of 3.77, ranking 33 out of 124 [3] Investment Sentiment - Over the past 90 days, 9 institutions have rated Kefu Medical with a buy recommendation, with an average target price of 53.84 yuan [4]

Core Insights - The stock of Kefu Medical (301087) closed at 42.78 yuan on November 19, 2025, with a slight increase of 0.12% and a trading volume of 11,500 hands, resulting in a transaction value of 49.04 million yuan [1][2]. Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, reflecting a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, up 38.68% year-on-year [3]. - The company's gross profit margin stands at 53.35%, with a net profit margin of 10.82% [3]. Market Position - Kefu Medical's total market capitalization is 8.937 billion yuan, ranking 42nd in the medical device industry, while its net assets amount to 4.75 billion yuan, ranking 29th [3]. - The company has a price-to-earnings ratio (P/E) of 25.76, significantly lower than the industry average of 56.7, placing it 23rd in the industry [3]. Investment Sentiment - Over the past 90 days, 9 institutions have rated Kefu Medical with a "buy" recommendation, and the average target price set by these institutions is 53.84 yuan [4].

Core Viewpoint - The stock of Kefu Medical (301087) has shown a slight decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][2]. Group 1: Stock Performance - As of November 18, 2025, Kefu Medical's stock closed at 42.73 yuan, down 0.56% with a turnover rate of 0.56% and a trading volume of 10,900 hands, resulting in a transaction amount of 46.80 million yuan [1]. - Over the past five days, the stock has experienced a downward trend, with a notable drop of 2.73% on November 13, 2025, and a total net outflow of main funds amounting to 470.54 thousand yuan on November 18, 2025 [2]. Group 2: Capital Flow Analysis - On November 18, 2025, the main funds saw a net outflow of 470.54 thousand yuan, accounting for 10.05% of the total transaction amount, while retail investors contributed a net inflow of 309.93 thousand yuan, representing 6.62% of the total [1][2]. - The capital flow data over the last five days indicates fluctuating investor behavior, with retail investors showing resilience despite the overall negative sentiment from main funds [2]. Group 3: Financial Metrics and Industry Comparison - Kefu Medical's total market capitalization stands at 8.93 billion yuan, with a net asset value of 4.75 billion yuan and a net profit of 260 million yuan, ranking 43rd, 29th, and 24th respectively within the medical device industry [3]. - The company reported a gross margin of 53.35% and a net profit margin of 10.82%, both of which are above the industry averages, indicating strong operational efficiency [3]. - For the first three quarters of 2025, Kefu Medical's main revenue reached 2.398 billion yuan, reflecting a year-on-year increase of 6.63%, while the net profit grew by 3.3% to 260 million yuan [3]. Group 4: Analyst Ratings - In the last 90 days, nine institutions have rated Kefu Medical with a "buy" recommendation, and the average target price set by these institutions is 53.84 yuan [4].